Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Raj Chovatiya, MD, PhD, discusses how oral TYK2 inhibitor zasocitinib may affect scalp, nail, and hand psoriasis, clearance speed, and once-daily dosing.

What Zasocitinib Data Mean for Scalp, Nail, and Hand Psoriasis

Raj Chovatiya, MD, PhD, explains where oral TYK2 inhibitor zasocitinib may fit in psoriasis treatment after the FDA accepted its NDA under priority review.

Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.

Q&A: Why APEX May Not Prove Guselkumab is Superior for PsA Joints

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

How Wildfire Smoke Triggers Allergic Disease Long After It Clears

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.

Q&A: How Trial Enrichment Shaped APEX's Radiographic Findings in Psoriatic Disease

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis 

David Oberlin, MD, on why trial enrichment, not mechanistic superiority, likely explains differing radiographic results in PsA drug trials.

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

6 Dermatology Headlines You Missed in August 2026

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

Ixekizumab-Tirzepatide Sustains 1-Year Gains in Psoriatic Disease, Obesity

Saakshi Khattri, MD, discusses a new JAAD dual Th17/type 2 signature study and what it means for personalized psoriasis care this Awareness Month.

A New Immune Signature and Path to Personalized Psoriasis Care, With Saakshi Khattri, MD

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis